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Background: Limited data exist regarding real-world treatment patterns, resource utilization, and costs of
extensive-stage small cell lung cancer (esSCLC) among elderly patients in the United States. While abundant data
are available on treatment patterns in metastatic non-small cell lung cancer (mNSCLC), to our knowledge no data
exist comparing costs and resource use between patients with esSCLC or mNSCLC.
Methods: We retrospectively analyzed administrative claims data (2000–2008) of patients aged ≥65 years from the
linked Surveillance, Epidemiology and End Results (SEER)-Medicare database. Patients were selected on the basis of
having newly diagnosed esSCLC (n=5,855) or mNSCLC (n=24,090) during 1/1/2000-12/31/2005, and were required
to have received cancer-directed therapy. Survival and other measures were compared between esSCLC and
mNSCLC patients using Kaplan-Meier log-rank and univariate chi-square and t-tests. Study measures were followed
from first diagnosis date of either esSCLC or mNSCLC until the earlier of death or end of the database.
Results: Survival between the cohorts did not differ significantly: mean of 10.4 months for esSCLC patients versus
11.1 months for mNSCLC; median survival was 7.4 months versus 5.9 months. A higher percentage of mNSCLC
patients (vs. esSCLC) received radiation therapy (75.6% vs. 65.4%; P < 0.001) and surgery (13.6% vs. 7.8%; P < 0.001)
during the metastatic disease period. Conversely, a higher percentage of esSCLC patients than mNSCLC patients
received chemotherapy (85.5% vs. 60.3%; P < 0.001), red blood-cell transfusion (20.7% vs. 10.9%; P < 0.001), platelet
transfusion (5.6% vs. 1.8%; P < 0.001), and growth-factor support (59.0% vs. 39.5%; P < 0.001). esSCLC patients incurred
higher lifetime disease-related costs ($44,167 vs. $37,932; P < 0.001) and all-cause costs ($70,549 vs. $67,176; P < 0.001)
than mNSCLC patients.
Conclusions: Lifetime total and disease-related costs per patient were high. Increased use of chemotherapy, supportive
care therapies (including growth factors), and disease-related hospitalizations were observed in esSCLC patients as
compared with mNSCLC patients. Disease-related and all-cause costs for esSCLC also exceeded those of mNSCLC,
except for hospice and skilled nursing services. Survival and per-patient costs for both groups underscore the unmet
medical need for more effective therapies in patients with esSCLC or mNSCLC.
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Lung cancer remains the second most commonly diag-
nosed cancer in the United States (US), with approximately
225,000 new cases and 160,000 deaths expected in 2014
[1]. Approximately 14% of new diagnoses are classified as
having small cell lung cancer (SCLC), while the remaining
85% of cases are non-small cell lung cancer (NSCLC)
[2]. Nearly two-thirds of these patients are diagnosed at
age 65 years or older, with an estimated median age at
diagnosis of 70 years [2]. Approximately 70% of SCLC
and 54% of NSCLC cases have metastasized to other
organs at initial diagnosis; this higher percentage of
SCLC patients diagnosed with extensive-stage disease
(esSCLC) likely contributes to its lower overall 5-year
survival rate (6.2%) versus that of mNSCLC (18.0%) [2].
For patients with mNSCLC, current and previous
guidelines recommend platinum-doublet chemotherapy as
first-line systemic treatment, although recommendations of
specific agents and/or combinations of agents have evolved
over time depending on disease histology (squamous or
non-squamous) and, more recently, presence of epidural
growth factor receptor (EGFR) and/or anaplastic lymph-
oma kinase (ALK) gene mutations [3]. For patients with
esSCLC, etoposide plus a platinum agent (cisplatin or
carboplatin) is the recommended first-line systemic
therapy [4]. For both lung cancer types, radiotherapy
may also be indicated either in sequential or concurrent
use with chemotherapy [3,4].
Lung cancer exerts a significant economic burden on
the US health care system. A recent study estimated that
in 2010, medical costs related to lung cancer were $12.1
billion and were expected to increase to $15.2 billion by
2020 [5]. Because the median age atf diagnosis in lung-
cancer patients is high (71 years) [2], this cost burden is
largely incurred by the US Medicare system. Despite
this burden and its expected future trend, limited data
exist comparing health care resource use and costs in
elderly patients with either esSCLC or mNSCLC [6,7].
Additonally, to our knowledge, there are no data
describing treatment patterns for esSCLC.
Most existing cost studies focus on mNSCLC alone
[8-10] or on all lung cancers combined [11-13]. Existing
cost studies have primarily focused on estimations of
chemotherapy use and costs [14-17], with little information
presented regarding broader treatment patterns, resource
utilization, and costs for other service categories. Only one
recently published US study addressed these knowledge
gaps, although the authors used data drawn from 1992 to
2003 [18].
To help meet these information needs, we conducted
a retrospective analysis of the linked Surveillance, Epi-
demiology and End Results (SEER)-Medicare database to
provide a summary of trends in treatment patterns, and




The SEER program, initiated by the National Cancer
Institute in 1973, collects cancer incidence and survival
data from population-based registries covering approxi-
mately 28% of the US population [19]. In this retro-
spective longitudinal cohort study, we analyzed the
SEER-Medicare linked database from 2000 through 2008.
At the time this study was conducted, the SEER-Medicare
database included new cancer cases first diagnosed
through 2005, with linked claims data available on these
subjects through 2008.
The data files utilized for this analysis were those
included in the standard SEER-Medicare file set avail-
able from the NCI: Patient Entitlement and Diagnosis
Summary File (PEDSF); Medicare Provider Analysis
and Review (MEDPAR) hospital file; Carrier Claims
(physician office visits) file; Outpatient (other ambulatory
care) file; Home Health Agency (home health services)
file; Hospice file; and Durable Medical Equipment file.
The conduct of this study was approved by an autho-
rized institutional review board: the Research Triangle
Institute (RTI) Committee on the Protection of Human
Subjects (Federal-Wide Assurance [FWA] #3331) is reg-
istered with the US Department of Health and Human
Services (DHHS) Office for Human Research Protections
(OHRP).
Patient selection
Patients with a new lung cancer diagnosis (International
Classification of Diseases for Oncology, Third Edition
[ICD-O-3] topography codes: C34.0-C34.9) between
January 1, 2000, and December 31, 2005, were selected
for initial inclusion. These patients were classified as
SCLC or NSCLC, using ICD-O-3 histology codes
8041–8045 for SCLC and 8046 for NSCLC [20]. We
further restricted the sample to patients with extensive-
stage and metastatic disease (esSCLC or mNSCLC) at
diagnosis, using tumor staging information provided in
the SEER data. Details on SEER cancer staging classifica-
tions are provided elsewhere [21]. For all selected patients,
the study index date was defined as the date of the first
SEER-reported diagnosis of esSCLC or mNSCLC. Fur-
thermore, the study cohort was limited to patients who
received cancer-directed therapy (surgery, radiation,
chemotherapy, biologic therapy) at some point on or
after their index date. All patients were required to be
65 years of age or older at first diagnosis and to have
age as their reason for Medicare eligibility. Patients also
were required to have at least 6 months of continuous
Medicare enrollment prior to their study index date.
Karve et al. BMC Health Services Research 2014, 14:555 Page 3 of 13
http://www.biomedcentral.com/1472-6963/14/555Patients were followed from the index date until the
earlier of death or end of the database. A minimum
post-index follow-up duration was not required for study
inclusion. Patients enrolled in a health maintenance
organization during the 6-month pre-index period or at
any time during post-index follow-up were excluded
[22,23]. Finally, we excluded patients with evidence of
other malignancies at any point pre- or post-index, except
for basal and squamous cell carcinomas of the skin which
are not reportable to SEER.
Study measures
Patient characteristics
Background characteristics of age, sex, race, US Census
region of residence, urban versus rural location of resi-
dence, and tumor histology were evaluated. Underlying
comorbidity burden was assessed using the Charlson
Comorbidity Index score (excluding diagnosis codes for
lung cancer) with the Deyo adaptation for claims data [24].
Treatment patterns
Treatment patterns associated with esSCLC and mNSCLC,
including supportive and palliative therapies, were defined
by the relevant Health Care Financing Administration
Common Procedure Coding System (HCPCS), Inter-
national Classification of Diseases, Ninth Revision, Clinical
Modifications (ICD-9-CM) procedure codes, and certain
ICD-9-CM diagnostic codes and administrative revenue
codes (see Additional file 1) recorded in the linked
Medicare claims data.
We documented detailed usage patterns of chemother-
apy including the most frequently observed first-, second-,
and third-line chemotherapy regimens. Specific regimen
compositions were defined by using algorithms developed
in previous claims-based studies of chemotherapy utili-
zation [9,14]. For first-, second-, and third-line chemo-
therapy regimens, we assessed the number of treatment
cycles that were administered to each patient by using
methods presented in recent claims-based cancer studies
by Ramsey et al. [13] and Weycker et al. [25].
Health care utilization and costs
Total all-cause and disease-related health care utilization
as well as costs were aggregated for each patient across
the entire available follow-up period and stratified by
major care settings: inpatient, outpatient, emergency
department, physician office, skilled nursing facility,
hospice, and other ancillary care. Disease-related health
care utilization and associated costs were defined as
claims for cancer-directed treatment or medical encoun-
ters or discharge records for inpatient admission carrying
a lung cancer ICD-9-CM diagnosis code [16,26].
Medicare-reimbursed amounts provided on each unique
claim in the database were used to assess all-cause anddisease-related costs. To approximate total lifetime costs,
all cost data associated with the selected service categories
were aggregated and reported as per-patient total costs
across all available follow-up, from study index date until
the earlier death or end of the database (December 31,
2008). Costs were inflated at the claim level to 2010 US
dollars using the medical component of the US Consumer
Price Index.Statistical analyses
Descriptive statistics that were generated for all analysis
variables included frequency distributions for categorical
variables, and mean values and standard deviations (SDs)
for continuous variables. The statistical significance of un-
adjusted differences in the outcomes of interest between
patient cohorts (esSCLC vs. mNSCLC) was measured
using Student t-tests and chi-square tests, as appropriate.
Kaplan-Meier survival curves and corresponding log-rank
tests were used to compare differences in survival time by
cancer type. Among patients who died during follow-up,
survival time was defined as the number of months be-
tween the study index date and the date of death. Among
patients who did not die during follow-up, survival time
was censored at the end of the database.Results
Patient characteristics
A total of 29,945 patients met all study inclusion cri-
teria: 5,855 (19.6%) of whom had esSCLC and 24,090
(80.4%) had mNSCLC (Figure 1). Patients differed sta-
tistically (P < 0.001) across all demographic characteris-
tics between the two lung-cancer types (Table 1). The
majority of patients in both cohorts were between the
ages of 65 and 74 years; esSCLC patients on average
were slightly younger than those with mNSCLC (73.5
vs. 74.4; p < 0.001). A greater number of patients in
both cohorts were male, white, and were more likely to
be located in the western part of the US in large metro-
politan areas. Approximately 20% of patients with
mNSCLC had tumors of squamous histology, while
41% had adenocarcinomas. While there were statistical
differences, the co-morbidity status (measured by mean
Charlson score) of both groups were comparable
(esSCLC: 1.6 [SD: 1.9] vs mNSCLC: 1.4 [SD 1.9]). Nearly
all patients (approximately 99%) from both study groups
died during the follow-up period. Survival time
between the cohorts did not differ significantly (log-
rank: P = 0.424): mean [standard error] survival was
10.4 [0.2] months for esSCLC patients versus 11.1
[0.1] months for mNSCLC patients; median survival
was 7.4 months (interquartile range [IQR]: 3 – 12.5)
versus 5.9 months (IQR: 2.9 – 12.5), respectively
(Figure 2).
Figure 1 Sample attrition chart. mNSCLC =metastatic non-small cell lung cancer; esSCLC = extensive-stage small cell lung cancer.
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Chemotherapy use was significantly more prevalent in
esSCLC patients than in mNSCLC patients (85.4% vs.
60.3%; P < 0.001) (Table 2), and fewer esSCLC patients
received surgery (7.8% vs. 13.6%; P < 0.001) and radiation
therapy (65.4% vs. 75.6%; P < 0.001). Approximately 46.7%
of esSCLC patients and 32.4% of mNSCLC patients
received both radiation and chemotherapy during the
follow-up period (P < 0.001). Radiation plus chemotherapy
was the only combination treatment approach seen with
substantial frequency in either cohort. Overall, the propor-
tion of patients receiving biologic therapy, which included
interleukin and interferon, was low in both the esSCLC
(1.8%) and mNSCLC (1.2%) cohorts.
Among esSCLC patients initiating chemotherapy, eto-
poside plus either carboplatin or cisplatin was the most
frequently observed first-line regimen, with a mean of
3.7 (carboplatin plus etoposide) and 3.4 (cisplatin plus
etoposide) total cycles administered (Figure 3). Of all
esSCLC patients receiving first-line chemotherapy, 43.2%
received a second-line regimen and 18.0% received athird-line regimen. Monotherapy with intravenous topote-
can was the most common regimen seen in second-line
(26.3%) and third-line initiators (20.8%) with esSCLC.
A carboplatin-based regimen was the most common
first-line therapy initiated in mNSCLC patients (65.6%)
with carboplatin plus paclitaxel being the most frequently
used (44.0%) combination, with a mean of 3.3 cycles
administered. Among mNSCLC patients initiating a first-
line regimen, 22.6% subsequently received second-line
therapy and 8.8% received third-line therapy. The most
commonly used second- and third-line regimens included
docetaxel (20.2%) and vinorelbine monotherapy (16.1%).
Utilization of supportive and other palliative therapies
during the follow-up period are presented in Table 2.
A significantly higher proportion of esSCLC patients
received growth-factor therapy than did mNSCLC
patients (59.0% vs. 39.5%; P < 0.001). Among patients who
required growth-factor support, erythropoietin (40.1%),
filgrastim (25.1%), and pegfilgrastim (21.6%) were the
most commonly used agents for esSCLC patients. For
mNSCLC patients, erythropoietin (28.4%), darbepoetin
Table 1 Baseline esSCLC and mNSCLC patient characteristics
Study groups P value
esSCLC mNSCLC
Overall, (n, %) 5,855 (100.0) 24,090 (100.0) ―
Age
Mean (SD) 73.5 (5.6) 74.4 (6.0) < 0.001
Age group, n (%)
65-74 years 3,474 (59.3) 12,911 (53.6) < 0.001
75-84 years 2,170 (37.1) 9,749 (40.5)
≥ 85 years 211 (3.6) 1,430 (5.9)
Gender, n (%)
Male 2,998 (51.2) 13,535 (56.2) < 0.001
Female 2,857 (48.8) 10,555 (43.8)
Race, n (%)
White 5,243 (89.6) 20,519 (85.2) < 0.001
Black 376 (6.4) 2,102 (8.7)
Other/unknown 236 (4.0) 1,469 (6.1)
Census region, n (%)
Northeast 1,303 (22.3) 5,620 (23.3) < 0.001
Midwest 941 (16.1) 3,521 (14.6)
South 1,482 (25.3) 5,397 (22.4)
West 2,129 (36.4) 9,552 (39.7)
Urban/rural status of residency, n (%)a
Big metro 3,029 (51.7) 13,331 (55.3) < 0.001
Metro 1,708 (29.2) 6,905 (28.7)
Urban 409 (7.0) 1,568 (6.5)
Less urban 566 (9.7) 1,865 (7.7)
Rural 143 (2.4) 421 (1.8)
Tumor histology, n (%)
esSCLC cases
Small cell carcinoma 5,855 (100.0) ― ―
mNSCLC cases
Squamous cell ― 4,865 (20.2) ―
Adenocarcinoma ― 9,816 (40.7) ―
Large Cell ― 1,363 (5.7) ―
Other specified carcinomas ― 316 (1.3) ―
Carcinomas unspecified ― 7,730 (32.1) ―
Charlson comorbidity index score
Mean (SD) 1.6 (1.9) 1.4 (1.9) < 0.001
mNSCLC =metastatic non-small cell lung cancer; esSCLC = extensive-stage small cell lung cancer; SD = standard deviation.
aUrban/rural definitions per SEER registry: Big Metro = counties in metro areas of >1 million population; Metro = counties in metro areas of ≤1 million population;
Urban = areas of ≥20,000 population adjacent/non-adjacent to (but not in) a metro area; Less Urban = areas of <20,000 population adjacent/non-adjacent to (but
not in) a metro area; Rural = completely rural or urban population <2,500 adjacent/non-adjacent to (but not in) a metro area.
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Among esSCLC patients who received either carboplatin
or etoposide chemotherapy, approximately 53% received
epoetin alfa and approximately 34% received filgrastimduring the follow-up period. Among esSCLC patients who
received topotecan, approximately 68% received epoetin
alfa and 44% received filgrastim. Among mNSCLC patients
who received either carboplatin or paclitaxel chemotherapy,
Figure 2 Kaplan-Meier survival curves, by tumor type. mNSCLC =metastatic non-small cell lung cancer; esSCLC = extensive-stage small cell
lung cancer.
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received filgrastim during follow-up (tabular data available
upon request).
A significantly higher proportion of esSCLC patients
received other supportive therapies than did mNSCLC
patients (Table 2): megestrol (38.9% vs. 25.2%; P < 0.001),
antiemetics (69.9% vs. 53.7%; P < 0.001), and red blood-
cell (20.7% vs. 10.9%; P < 0.001) and platelet transfusions
(5.6% vs. 1.8%; P < 0.001). mNSCLC patients received
bisphosphonates with significantly greater frequency
than patients with esSCLC (9.4% vs 6.4% P <0.001). The
frequency in esSCLC and mNSCLC, respectively, of anti-
biotics (10.5% vs 9.7%; p = 0.063), pain medications (23.3%
vs 24.0%; P =0.280), and oxygen (29.0% vs 28.5%; P =0.118)
utilization was similar between the two groups.
Health care utilization and costs
The percentage of patients with at least one hospital-
ization for any cause was high for both cohorts (esSCLC
vs. mNSCLC: 91.4% vs. 88.6%; P < 0.001) (Table 3). Exam-
ining lung-cancer–specific hospitalizations, the frequency
of post-index hospitalization was significantly higher in
esSCLC patients than in mNSCLC patients (55.9% vs.
44.9%; P < 0.001), as was average total inpatient days
(mean [SD]: 7.5 [11.1] vs. 5.4 [9.3] days; P < 0.001). For all
other categories evaluated, disease-related health care
resource utilization occurred with greater frequency formNSCLC patients while all-cause health care utilization
was comparable between the two groups.
Per-patient total all-cause health care costs over all
available follow-up among esSCLC patients exceeded those
of mNSCLC patients ($70,549 vs. $67,176; P < 0.001)
(Table 4). In both cohorts, hospitalization was the predom-
inant cost driver, followed by office visits, the typical setting
in which outpatient chemotherapy is administered. The
mean numbers of all-cause inpatient visits (2.6 vs. 2.3;
P = 0.001) and office visits (44.3 vs. 39.2; P < 0.001) were
higher for esSCLC patients than for mNSCLC patients.
In examining disease-related costs, office visits were
proportionately the largest cost driver, accounting for
43% of all disease-related costs to esSCLC patients and
approximately 41% of disease-related costs to mNSCLC
patients. Among esSCLC patients, total disease-related
per-patient costs for all available follow-up were 16.4%
higher than for mNSCLC patients ($44,167 vs. $37,932;
P < 0.001). Per-month costs for esSCLC patients were
17.2% higher ($6,702 vs. $5,721; P < 0.001) than for
mNSCLC patients.
Discussion
Our study confirms the substantial economic burden
presented by patients with esSCLC and mNSCLC who
were enrolled in the US Medicare system and who
received cancer-directed treatment during 2000–2008.
Table 2 Treatment utilization among esSCLC and mNSCLC patients, by tumor type
Study groups P value
esSCLC mNSCLC
(N = 5,855) (N = 24,090)
Post-index prevalence of cancer-directed therapies
Overall, n (%)a
Surgery 458 (7.8) 3,278 (13.6) < 0.001
Radiation therapy 3,827 (65.4) 18,208 (75.6) < 0.001
Biologic therapy 103 (1.8) 282 (1.2) < 0.001
Chemotherapy 5,003 (85.4) 14,527 (60.3) < 0.001
No. cycles received in first-line treatment, mean (SD) 3.4 (2.1) 3.2 (2.3)
Post-index prevalence of supportive or palliative therapies
Growth factors, n (%)a
Filgrastim/pegfilgrastim/sargramostim 2,483 (42.4) 4,275 (17.8) < 0.001
Darbepoetin/erythropoietin 2,926 (50.0) 8,640 (35.9) < 0.001
Any growth factor 3,453 (59.0) 9,506 (39.5) < 0.001
Other supportive or palliative therapies, n (%)a
Iron supplements 39 (0.7) 249 (1.0) 0.012
Antibiotics 613 (10.5) 2,328 (9.7) 0.063
Antiemetics 4,095 (69.9) 12,947 (53.7) < 0.001
Antifungalsb 21 (0.1)
Pain medications 1,366 (23.3) 5,782 (24.0) 0.280
Bisphosphonates 373 (6.4) 2,271 (9.4) < 0.001
Megestrol acetate 2,276 (38.9) 6,078 (25.2) < 0.001
Oxygen 1,696 (29.0) 6,861 (28.5) 0.118
Red blood-cell transfusion 1,212 (20.7) 2,629 (10.9) < 0.001
Platelet transfusion 330 (5.6) 426 (1.8) < 0.001
mNSCLC = non-small cell lung cancer; esSCLC = small cell lung cancer.
aCategories are not mutually exclusive.
bPer National Cancer Institute protocol, data suppressed due to cell size <11.
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all cost categories were at least as high and in most
instances higher than for the mNSCLC cohort, with the
exception of hospice and skilled nursing facility ser-
vices. The primary drivers of costs for the esSCLC and
mNSCLC cohorts were hospitalizations, office visits,
and hospital outpatient visits.
Despite statistically significant differences between clin-
ical and demographic characteristics, the distribution of
patients in the esSCLC and mNSCLC cohorts by age, gen-
der, race, census region, and urban versus rural status of
residency at baseline were comparable. The mean age and
Charlson Comorbidity Index scores were also similar.
In our study, approximately 71% of patients with esSCLC
initiated a first-line chemotherapy regimen of etoposide
with cisplatin or carboplatin, which was considered the
recommended standard regimen for esSCLC during the
period studied [27-30]. A clinical trial published in 2002reported improved survival among esSCLC patients using
irinotecan plus cisplatin when compared with patients
using etoposide with cisplatin [31]. However, more recent
studies reported no additional survival benefit from
using irinotecan-plus-cisplatin combination therapy ver-
sus etoposide-plus-cisplatin. Therefore, it was expected
that utilization data from 2008 to the present may reflect
different patterns compared with our data from 2000–
2008 [32,33]. Overall, in our study, irinotecan in combin-
ation with cisplatin was the third most commonly used
first-line chemotherapy regimen among esSCLC patients.
There was significant heterogeneity with esSCLC regi-
mens used in second- and third-line therapy, reflecting
the lack of standard treatment options for these settings.
In our study, intravenous topotecan was the predominant
regimen in both the second line (26.3%) and the third line
(20.8%) for esSCLC patients, followed by carboplatin plus
etoposide (18.1% of second-line initiators, 11.7% of third-
Figure 3 Chemotherapy utilization patterns, by tumor type. CYCL + DOX + VINC = cyclophosphamide + doxorubicin + vincristine;
HCPCS = Healthcare Common Procedure Coding System; NSCLC = non-small cell lung cancer; SCLC = small cell lung cancer. Notes: Top 10
most frequently used regimens. Real-world data may show both approved and non-approved single agent and/or combination therapies
(e.g. gemcitabine is indicated in combination with cisplatin for the first-line treatment of mNSCLC). Denominator for the estimated frequency
distribution includes only patients initiating a HCPCS-identifiable first-, second-, or third-line chemotherapy regimen. For the esSCLC cohort, there were
4,256 patients initiating an HCPCS-identifiable first-line chemotherapy regimen, 1,824 patients initiating an HCPCS-identifiable second-line chemotherapy
regimen, and 758 patients initiating an HCPCS-identifiable third-line chemotherapy regimen. For the mNSCLC cohort, there were 13,298 patients initiating
an HCPCS-identifiable first-line chemotherapy regimen, 5,485 patients initiating an HCPCS-identifiable second-line chemotherapy regimen, and 2,108
patients initiating an HCPCS-identifiable third-line chemotherapy regimen.
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approved by the US Food and Drug Administration (FDA)
for platinum-sensitive esSCLC patients after failure of
first-line therapy, despite demonstrating nonsignificant
differences in efficacy outcomes when compared with
cyclophosphamide, doxorubicin, and vincristine [34]. The
relatively high usage of these therapies, with lack of
improved survival outcomes from the registration trial,may reflect the greater need for and lack of impactful
treatment alternatives for esSCLC patients. The US FDA
also approved oral topotecan for patients with relapsed
esSCLC on the basis of significantly improved differences
in overall survival versus best supportive care (log-rank:
P = 0.0104) [35]. Because of limited claims data from the
Medicare Part D program, we were not able to capture
the use of oral topotecan, but this information has
Table 3 Overall health care utilization among esSCLC and mNSCLC patients, by tumor type
Study groups P value
esSCLC mNSCLC
(N = 5,855) (N = 24,090)
Hospitalizations
All cause
Had ≥1 admission, n (%) 5,349 (91.36) 21,351 (88.63) < 0.001
Mean (SD) number of admissions 2.56 (2.16) 2.28 (1.96) 0.001
Mean (SD) total days in hospital 17.79 (17.37) 16.40 (17.34) < 0.001
Disease related
Had ≥1 admission, n (%) 3,272 (55.88) 10,825 (44.94) < 0.001
Mean (SD) number of admissions 0.91 (1.25) 0.61 (0.86) < 0.001
Mean (SD) total days in hospital 7.47 (11.09) 5.40 (9.31) < 0.001
ER visits
All cause
Had ≥1 visit, n (%) 4,850 (82.84) 19,393 (80.50) < 0.001
Mean (SD) number of visits 2.32 (2.38) 2.20 (2.36) < 0.001
Disease related
Had ≥1 visit, n (%) 2,295 (39.20) 9,145 (37.96) 0.081
Mean (SD) number of visits 0.54 (1.05) 0.66 (1.17) 0.003
Office visits
All cause
Had ≥1 visit, n (%) 5,789 (98.87) 23,764 (98.65) 0.172
Mean (SD) number of visits 44.27 (43.57) 39.18 (43.79) < 0.001
Disease-related
Had ≥1 visit, n (%) 5,527 (94.40) 22,915 (95.12) 0.023
Mean (SD) number of visits 22.93 (31.00) 31.82 (32.93) < 0.001
Hospital outpatient visits
All cause
Had ≥1 visit, n (%) 5,320 (90.86) 22,018 (91.40) 0.192
Mean (SD) number of visits 13.05 (16.69) 12.18 (16.78) < 0.001
Disease related
Had ≥1 visit, n (%) 4,846 (82.77) 19,881 (82.53) 0.666
Mean (SD) number of visits 6.47 (11.35) 8.97 (12.65) < 0.001
Hospice visits
All cause
Had ≥1 visit, n (%) 3,091 (52.79) 12,982 (53.89) 0.131
Mean (SD) number of visits 1.17 (2.12) 1.30 (2.57) < 0.001
Disease related
Had ≥1 visit, n (%) 2,927 (49.99) 12,104 (50.24) 0.728
Mean (SD) number of visits 1.04 (2.22) 1.10 (2.05) < 0.001
Skilled nursing facility care
All cause
Had ≥1 visit, n (%) 1,497 (25.57) 6,171 (25.62) 0.939
Mean (SD) number of visits 0.37 (0.79) 0.37 (0.77) 0.652
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Table 3 Overall health care utilization among esSCLC and mNSCLC patients, by tumor type (Continued)
Disease related
Had ≥1 visit, n (%) 1,211 (20.68) 4,829 (20.05) 0.276
Mean (SD) number of visits 0.24 (0.60) 0.28 (0.66) 0.026
Ancillary care
All cause
Had ≥1 visit, n (%) 4,070 (69.51) 16,455 (68.31) 0.075
Mean (SD) number of visits 5.94 (10.07) 5.62 (11.14) 0.049
Disease related
Had ≥1 visit, n (%) 3,035 (51.84) 11,793 (48.95) < 0.001
Mean (SD) number of visits 1.96 (4.58) 2.65 (5.25) < 0.001
ER = emergency department; mNSCLC =metastatic non-small cell lung cancer; esSCLC = extensive-stage small cell lung cancer; SD = standard deviation.
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Approximately 40% of patients in the mNSCLC cohort
and 60% of patients in the esSCLC cohort received either
an erythropoietic therapy (ESA) or myeloid growth factor
during the follow-up period. Pegfilgrastim, filgrastim,
and sargramostim use was 42.4% across lines of therapy
among esSCLC patients, and use was significantly greater
than patients with mNSCLC (17.8%). Darbepoetin/
erythropoietin use was also fairly high across both
esSCLC (50%) and mNSCLC (35.9%) cohorts. A high
rate of growth-factor use (>50%) in the real-world set-
ting has been reported previously, despite low support
of its use by the American Society of Clinical Oncology
[36]. According to current guidelines by the National
Comprehensive Cancer Network (NCCN), use of myeloid
growth factor is not routinely recommended for primary
prophylaxis in esSCLC or mNSCLC patients receiving
chemotherapy. However, such therapy is recommended
and should be considered after risk factor assessment in
patients who are at high (>20%) or intermediate (10%-
20%) risk for developing febrile neutropenia. NCCN
strongly prefers that a less myelosuppressive therapy be
used or dose reductions be considered so long as efficacyTable 4 Mean all-cause and disease-related health care costs
All cause Disease-related
esSCLC ($) mNSCLC ($) esSCLC ($) mNS
Hospitalizations 32,456 32,027 12,498 9
Office Visits 22,340 18,995 19,168 15
Hospital OP Visits 7,253 7,040 6,044 5
Hospice 3,099 3,693 2,933 3
Other Ancillary Care 2,624 2,502 1,656 1
Skilled Nursing Facility 2,453 2,607 1,790 1
ER Visits 324 312 78
Total 70,549 67,176 44,167 37
ER = emergency department; mNSCLC =metastatic non-small cell lung cancer; OP =outcomes are not compromised [37]. NCCN guidelines
that were in place during the observation period of our
study reflect these same considerations [38].
Guidelines for ESA use evolved from 2002 to 2008 due
to the increasing knowledge over time regarding safety of
these agents. Prior to 2007, the guidelines recommended
ESAs in an effort to avoid transfusions and improve
patient quality of life. However, since that time an in-
creasing amount of data became available outlining the
thrombosis risk and potential negative impact on patient
survival. This not only prompted black box warnings by
FDA for these agents, but changed the guideline recom-
mendation in 2008 to exclude use in patients who could
be cured of their disease. Additonally, the hemaglobin
target was lowered from twelve to ten grams per deciliter.
The 2008 guideline also communicated the thrombosis
and mortality risk associated with blood transfusions, and
urged patients to thoroughly discuss the risks and benefits
of both ESA use and/or blood transfusions with their
physician [39].
The availability of data outlining concerns associated
with ESA use, black box warnings, and changes in treat-
ment recommendations all occurred during the latter
portion of our study period. We did not conduct a trendamong esSCLC and mNSCLC patients, by tumor type
esSCLC vs. mNSCLC
CLC ($) P value (All-cause costs) P calue (Disease-related costs)
,778 0.403 < 0.001
,622 < 0.001 < 0.001
,767 0.270 0.116




,932 < 0.001 < 0.001
outpatient; esSCLC = extensive-stage small cell lung cancer.
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or ESAs given that our observation period ended in 2008;
this did not allow enough time to observe a meaningful
trend. Further research is warranted in the esSCLC and
mNSCLC populations to characterize the trajectory of
this information over time. These data suggest that use
of ESAs did indeed decrease over time due to changing
guidelines as well as subsequent reimbursement stipula-
tions [40]. While the assessment of side effects associated
with chemotherapy was beyond the scope of this project,
the higher use of chemotherapy among esSCLC pa-
tients (85.5%) than mNSCLC patients (60.3%) could
have contributed to a higher rate of side effects (e.g.,
chemotherapy-induced nausea and vomiting), resulting
in greater use of supportive care therapies, greater
health care utilization, and associated costs [41,42]. In
addition to growth factor use, there was significantly
greater use of antiemetics and megesterol acetate; as
well as RBC and platelet tranfusions in patients with
esSCLC. Additionally, a greater proportion of esSCLC
patients had at least one hospitalization and spent on
average 1.5 days longer in the hospital. These findings
may be a reflection of the negative sequelae that can be
associated with chemotherapy use (and its more signifi-
cant use among esSCLC patients) and may also reflect the
aggressiveness of esSCLC. Further research is necessary to
assess the costs associated with chemotherapy-related side
effects for esSCLC and mNSCLC patients [43].
Among mNSCLC patients, we found that 75.6% received
radiation which is recommended as palliation according
to NCCN [44], and to help prevent symptoms due to
primary or metastatic tumors. In our study, approximately
two-thirds of mNSCLC patients initiating chemotherapy
received carboplatin in combination with paclitaxel, doce-
taxel, or gemcitabine; this is consistent with prior research
and recommendations during the time period of our study
[45-48], but may not always match the product labels.
It is important to note that more recent advancements
in mNSCLC are not fully captured in our data, either
because there was minimal time from the availabilty of
a new therapy to the end of our observation period or
because therapies were approved after the end of our
study period. This includes the US FDA approvals for
bevacizumab, erlotinib, pemetrexed, nab-paclitaxel, afati-
nib, gefitinib, crizotinib, and ceritinib. This is a significant
limitation of the generalizability of mNSCLC treatment
pattern data in our study to current practice.
The lack of oral prescription drug data (i.e., Medicare
Part D) in our study further contributed to the conserva-
tive nature of our cost estimates and limited our ability
to gain information relative to erlotinib and topotecan
use in mNSCLC patients and esSCLC patients, respect-
ively. We recommend that these analyses be updated
now that these claim data are available.A few additional limitations must be considered when
interpreting these study findings. First, our analysis did
not include clinical trial participants or patients receiving
only supportive care; this likely underestimated the total
economic burden of esSCLC and mNSCLC. Second, our
definition of lung-cancer–specific treatment (chemother-
apy, radiation) was based on HCPCS and ICD-9-CM diag-
nosis and procedure codes; any coding inaccuracies could
lead to misclassification of these treatments. Third, our
method of estimating disease-related costs accounted only
for adjudicated medical claims carrying a lung-cancer
diagnosis code or claim for treatments and procedures
(chemotherapy, surgery, radiation) that were likely to be
cancer related. This microcosting approach likely under-
states the true direct costs to Medicare of lung-cancer
management because other treatments and other medical
services not considered in the definition are likely to be
utilized in the management of the disease. We therefore
also assessed all-cause resource utilization, which likely
overstated actual costs. Fourth, this analysis was limited to
elderly Medicare enrollees with distant-stage lung cancer.
While this is the subpopulation in which lung cancer
occurs most often, our results may not be generalizable to
younger adults, individuals enrolled in other federal or
commercial health plans, individuals without health cover-
age, or individuals with localized- or regional-stage lung
cancer. Finally, while this study was conducted using the
most up-to-date SEER-Medicare data at the time, more
recent data are now available. As noted above, while this
is a significant limitation in terms of the mNSCLC treat-
ment pattern data, it is not believed to be a limitation to
the accuracy of the cost and HCRU data. Since there have
been no recent advancements in the treatment of esSCLC,
the data used in this study remain representative and
informative with regard to real-world treatment patterns,
costs, and survival in these patients.
Conclusion
In conclusion, our study demonstrated that the direct
medical costs of both esSCLC and mNSCLC are substan-
tial and comparable; with a growing elderly population,
this cost burden to the Medicare system will increase in
the future. Additionally, therapies that provide clinically
meaningful improvements in efficacy, safety, and less
frequent dosing may help lower treatment-specific and
future downstream costs. In contrast to mNSCLC,
distant-stage esSCLC has had few therapies introduced
that have advanced overall survival, thus underscoring
the unmet need in this particular population of patients
with lung cancer. Overall, the similar survival estimates
and the significant per-patient lifetime costs for esSCLC
and metastatic mNSCLC underscore the unmet medical
need for patients with these tumor types. Our study
findings complement existing literature and may help
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and model inputs to Medicare-based cost-effectiveness
studies of interventions focused on prevention of lung
cancer or prevention of progression to the advanced-
disease stage.
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